U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07190469) titled 'A Phase 1 Study of PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer' on Aug. 19.
Brief Summary: The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.
Study Start Date: Sept. 16
Study Type: INTERVENTIONAL
Condition:
Triple Negative Breast Cancer (TNBC)
Advanced Solid Tumors Cancer
Intervention:
DRUG: PQ203
PQ203 is a peptide drug-conjugate given once weekly by intravenous infusion intended for the treatm...